Log in

NASDAQ:NVCRNovocure Stock Price, Forecast & News

$60.38
+0.31 (+0.52 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$59.80
Now: $60.38
$60.78
50-Day Range
$57.20
MA: $63.70
$70.12
52-Week Range
$53.40
Now: $60.38
$98.84
Volume270,738 shs
Average Volume1.02 million shs
Market Capitalization$6.06 billion
P/E Ratio670.96
Dividend YieldN/A
Beta1.54
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.06 billion
Next Earnings Date7/30/2020 (Confirmed)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock been impacted by COVID-19 (Coronavirus)?

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have decreased by 10.4% and is now trading at $60.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novocure?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Novocure.

How can I listen to Novocure's earnings call?

Novocure will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, April, 30th. The medical equipment provider reported $0.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical equipment provider earned $101.83 million during the quarter, compared to analyst estimates of $102.10 million. Novocure had a net margin of 2.34% and a return on equity of 4.39%. The business's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. View Novocure's earnings history.

What price target have analysts set for NVCR?

8 brokers have issued 12-month price objectives for Novocure's shares. Their forecasts range from $58.00 to $90.00. On average, they expect Novocure's share price to reach $79.00 in the next twelve months. This suggests a possible upside of 30.8% from the stock's current price. View analysts' price targets for Novocure.

Has Novocure been receiving favorable news coverage?

News headlines about NVCR stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Novocure.

Are investors shorting Novocure?

Novocure saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,070,000 shares, an increase of 9.1% from the June 15th total of 3,730,000 shares. Based on an average daily volume of 885,100 shares, the short-interest ratio is presently 4.6 days. Approximately 4.9% of the company's stock are short sold. View Novocure's Current Options Chain.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Who are Novocure's major shareholders?

Novocure's stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View institutional ownership trends for Novocure.

Which institutional investors are buying Novocure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $60.38.

How big of a company is Novocure?

Novocure has a market capitalization of $6.06 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.